![]() |
市場調查報告書
商品編碼
1831917
計算生物學市場報告(按應用、服務、最終用途和地區)2025-2033Computational Biology Market Report by Application, Services, End Use, and Region 2025-2033 |
2024年,全球計算生物學市場規模達68億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到322億美元,2025-2033年期間的複合年成長率(CAGR)為17.83%。臨床研究數量的增加以及先進技術的整合推動市場的發展。目前,北美佔據最大的市場佔有率,這得益於領先的製藥和生物技術公司的存在以及公司之間的各種合作。
計算生物學,也稱為生物資訊學,是一門跨學科的科學分支,它運用數學、統計學和電腦科學來理解和建模生命的結構和過程。它涉及生物學的各個方面,例如遺傳學、進化論、細胞生物學和生物化學。該過程使用包括演算法在內的計算技術來表示和模擬生物系統,並大規模地解釋實驗資料。計算生物學還透過創建包含氨基酸序列、核苷酸和大分子結構的生物資訊資料庫,幫助理解疾病的治療方法和細胞功能。如今,計算生物學已成為包括人類基因組計畫、蛋白質資料和基因組資料庫在內的生物研究計畫的重要組成部分。
全球計算生物學市場主要受藥物基因組學領域臨床研究數量的不斷成長所驅動。這有助於加深對患者群體多樣化生物組成、生物途徑及其背後的基因組的理解。因此,對計算生物學解決方案的需求很高,因為它們有助於減少藥物研發和其他各種科學實驗所需的總時間。該過程還有助於可視化工具,以模擬高級藥物交互作用。此外,表觀基因組學、蛋白質組學和宏基因組學對計算生物學日益成長的需求,以了解蛋白質結構和相互作用,也推動了市場的成長。此外,藥物開發和疾病建模領域的各種技術進步,以及私人和政府機構在研發活動方面不斷增加的投資,預計也將在不久的將來為市場提供積極的推動力。
The global computational biology market size reached USD 6.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 32.2 Billion by 2033, exhibiting a growth rate (CAGR) of 17.83% during 2025-2033. The market is being driven by the rising number of clinical studies, along with integration of advanced technologies. At present, North America holds the largest market share, driven by the presence of leading pharmaceutical and biotechnology companies and various collaborations among companies.
Computational biology, also known as bioinformatics, is the interdisciplinary branch of science that uses math, statistics and computer science for understanding and modeling the structures and processes of life. It involves various aspects of biology, such as genetics, evolution, cell biology, and biochemistry. The process uses computational techniques, including algorithms, to represent and simulate biological systems and interpret experimental data on a large scale. Computational biology also helps understand the treatment for diseases and cellular function by creating a database of biological information from amino-acid sequences, nucleotides, and macromolecular structures. Nowadays, computational biology has become an essential part of biological research projects, including the human genome project, protein data banks and genomic databases.
The global computational biology market is primarily driven by the rising number of clinical studies in the field of pharmacogenomics. This has helped increase the understanding of the diverse biological makeup of the patient population, biological pathways, and the genomes underpinning them. As a result, there is a high demand for computational biology solutions, as they help reduce the overall time needed for drug discovery and various other scientific experiments. The process also aids the visualization of tools to simulate advanced drug-drug interactions. In addition to this, the growing demand for computational biology in epi-genomics, proteomics, and meta-genomics to undertint protein structures and interactions is also propelling the market growth. Furthermore, various technological advancements in drug development and disease modeling, along with increasing investments by private and government organizations in research and development (R&D) activities, are also anticipated to provide a positive thrust to the market in the near future.
Cellular and biological simulation accounts for the majority of the market share
Researchers can better comprehend basic biological processes and the course of disease by using cellular and biological modeling. Cellular simulations are essential to drug discovery because they allow for virtual chemical screening, drug interaction prediction, and lead candidate optimization. As a result, this reduces the time and cost associated with traditional experimental approaches. The accuracy and dependability of cellular and biological simulations are improved by the development of complex simulation software and algorithms such as agent-based modeling and systems biology techniques. A thorough grasp of biological activities is made possible by the integration of simulations with proteomic, metabolomic, and genomic data.
Contract holds the largest share of the industry
Contract services provide cost-effective solutions compared to maintaining in-house capabilities, particularly for smaller companies or those with limited resources. This trend is fostering more organizations to engage third-party providers for computational biology services. Contract service providers usually have access to the latest computational tools, technologies, and methodologies that allow clients to benefit from state-of-the-art solutions without the need for significant investment in infrastructure. Furthermore, contract services offer flexibility and scalability that allow companies to adjust the level of support based on project requirements.
Commercial represents the leading market segment
The creation of novel treatments is becoming a top priority for commercial enterprises, necessitating the use of sophisticated computational tools for biological system modeling, medication interaction prediction, and data analysis. The commercial segment is growing as a result of pharmaceutical and biotechnology businesses' substantial spending in research and development (R&D) activities. Computational biology solutions are being used by businesses more and more in order to obtain a competitive edge in drug discovery. The integration of data science and machine learning (ML) into drug development processes is leading to a higher adoption of computational biology techniques in commercial settings.
North America leads the market, accounting for the largest computational biology market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for computational biology.
North America is home to many leading pharmaceutical and biotechnology companies. The demand for computational biology solutions is significant in this region, as companies seek to streamline drug discovery and enhance their research and development (R&D) processes. The presence of well-established research institutions, universities, and laboratories equipped with advanced technologies fosters a conducive environment for computational biology. These institutions often collaborate with commercial entities, further driving the demand for computational services. Furthermore, top players in the region are developing new tools and methodologies that enhance research capabilities.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Certara, Chemical Computing Group ULC, Compugen Ltd, Dassault Systemes, Genedata AG, Insilico Biotechnology AG, Instem plc, Nimbus Therapeutics LLC, Schrodinger Inc. and Simulations Plus Inc.